Form 8-K - Current report:
SEC Accession No. 0001193125-24-066826
Filing Date
2024-03-13
Accepted
2024-03-13 16:08:03
Documents
15
Period of Report
2024-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d742679d8k.htm   iXBRL 8-K 25469
2 EX-99.1 d742679dex991.htm EX-99.1 56954
  Complete submission text file 0001193125-24-066826.txt   214600

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA scph-20240313.xsd EX-101.SCH 2881
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE scph-20240313_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scph-20240313_pre.xml EX-101.PRE 11282
16 EXTRACTED XBRL INSTANCE DOCUMENT d742679d8k_htm.xml XML 3633
Mailing Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803
Business Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Filer) CIK: 0001604950 (see all company filings)

EIN.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38293 | Film No.: 24745976
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)